Covid-19 Research

Case Report

A Typical Neuroleptic Malignant Syndrome Presenting with Hyponatremia

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Case Report
Subject Medicine Group
OCLC JBRES Record
Rustem O*, Ercan Y and Ozer O
Issue: Volume6-Issue8
Pages: 1138-1142
Received: 2025-06-26
Accepted: 2025-08-13
Published: 2025-08-27

Abstract

Neuroleptic Malignant Syndrome (NMS) is a rare but potentially fatal neurological complication of medications affecting the central dopaminergic system, especially antipsychotic agents. According to one theory, decreased dopamine activity in the central nervous system plays a role in the pathogenesis of NMS. Clinically, patients exhibit resistant fever, neurological and autonomic findings, and laboratory changes. In this article, we aimed to present a case of neuroleptic malignant syndrome due to a single dose of venlafaxine, which presented with hyponatremia and high fever.

FullText HTML FullText PDF DOI: 10.37871/jbres2171 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2025 Rustem O, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Rustem O, Ercan Y, Ozer O. A Typical Neuroleptic Malignant Syndrome Presenting with Hyponatremia. J Biomed Res Environ Sci. 2025 Aug 27; 6(8): 1138-1142. doi: 10.37871/jbres2171, Article ID: JBRES2171, Available at: https://www. jelsciences.com/articles/jbres2171.pdf

Subject area(s)

PsychiatryInternal MedicineNeurology

References

  1. Erol A, Putgül G, Sert E, Mete L. Klozapin kullanımına bağlı nöroleptik malign sendrom ve ardışık katatoni: olgu sunumu [Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report]. Turk Psikiyatri Derg. 2013 Summer;24(2):140-4. Turkish. PMID: 23754268.
  2. Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai. 2006 Dec;89(12):2155-60. PMID: 17214072.
  3. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. Curr Neuropharmacol. 2015;13(3):395-406. doi: 10.2174/1570159x13999150424113345. PMID: 26411967; PMCID: PMC4812801.
  4. Sarkar P, Natarajan C, Gode N. Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J Psychiatry. 2009 Jul-Sep;51(3):202-5. doi: 10.4103/0019-5545.55089. PMID: 19881049; PMCID: PMC2772217.
  5. Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017 May;135(5):398-408. doi: 10.1111/acps.12694. Epub 2017 Feb 1. PMID: 28144982.
  6. Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother. 2016 Nov;50(11):973-981. doi: 10.1177/1060028016657553. Epub 2016 Jul 19. PMID: 27423483.
  7. Xi A, Royce-Nagel G. 160: Treatment and complications of neuroleptic malignant syndrome. Critical Care Medicine. 2019;47(1):62. doi: 10.1097/01.ccm.0000550915.79019.18.
  8. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality. Neurocrit Care. 2016 Feb;24(1):97-103. doi: 10.1007/s12028-015-0162-5. PMID: 26223336.
  9. Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017 Jan 16;13:161-175. doi: 10.2147/NDT.S118438. PMID: 28144147; PMCID: PMC5248946.
  10. Nagel M, Freisberg S, Junghanns K, Moll CK, Willenborg B. Das maligne neuroleptische Syndrom (MNS)--Eine systematische Ãœbersicht [The Neuroleptic Malignant Syndrome]. Fortschr Neurol Psychiatr. 2015 Jul;83(7):373-80. German. doi: 10.1055/s-0035-1553246. Epub 2015 Jul 22. PMID: 26200042.
  11. Doğan N, Kürşad H, Erdem AF, kızılkaya M. Noroleptik malign sendromda nadir etyolojikfaktorlerveklinikseyir. AUTD 2003;35:23-6.
  12. Buckley PF, Hutchinson M. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):271-3. doi: 10.1136/jnnp.58.3.271. PMID: 7897404; PMCID: PMC1073359.
  13. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870-6. doi: 10.1176/ajp.2007.164.6.870. PMID: 17541044.
  14. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ. 2003 Sep 2;169(5):439-42. PMID: 12952806; PMCID: PMC183299.
  15. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008 Sep;42(9):1290-7. doi: 10.1345/aph.1L066. Epub 2008 Jul 15. PMID: 18628446.
  16. İşeri P, Selekler M. Nöroleptik malign sendrom. TurkiyeKlinikleri J Int Med Sci. 2005;1(5):39-42.
  17. Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl). 2015 Jan;232(1):1-5. doi: 10.1007/s00213-014-3807-8. Epub 2014 Nov 20. PMID: 25407348.
  18. Portel L, Hilbert G, Gruson D, Favier JC, Gbikpi-Benissan G, Cardinaud JP. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand. 1999 Jan;43(1):107-10. doi: 10.1034/j.1399-6576.1999.430123.x. PMID: 9926200.
  19. Sangal R, Dimitrijevic R. Neuroleptic malignant syndrome. Successful treatment with pancuronium. JAMA. 1985 Nov 15;254(19):2795-6. PMID: 4057490.
  20. Pierantozzi M, Sabato AF, Leonardis F, Marciani MG, Cicardi C, Giacomini P, Bernardi G, Stanzione P. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes. Exp Brain Res. 2000 Aug;133(3):368-76. doi: 10.1007/s002210000387. PMID: 10958527.
  21. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999 Feb;156(2):169-80. doi: 10.1176/ajp.156.2.169. PMID: 9989551.
  22. Mills EM, Banks ML, Sprague JE, Finkel T. Pharmacology: uncoupling the agony from ecstasy. Nature. 2003 Nov 27;426(6965):403-4. doi: 10.1038/426403a. PMID: 14647371.
  23. Blessing WW, Seaman B, Pedersen NP, Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci. 2003 Jul 16;23(15):6385-91. doi: 10.1523/JNEUROSCI.23-15-06385.2003. PMID: 12867524; PMCID: PMC6740548.
  24. Zaretsky DV, Zaretskaia MV, Durant PJ, Rusyniak DE. Inhibition of the dorsomedial hypothalamus, but not the medullary raphe pallidus, decreases hyperthermia and mortality from MDMA given in a warm environment. Pharmacol Res Perspect. 2014 Apr 1;2(2):e00031. doi: 10.1002/prp2.31. PMID: 24765530; PMCID: PMC3994179.
  25. Pedersen NP, Blessing WW. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci. 2001 Nov 1;21(21):8648-54. doi: 10.1523/JNEUROSCI.21-21-08648.2001. PMID: 11606652; PMCID: PMC6762811.
  26. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005 Nov;89(6):1277-96. doi: 10.1016/j.mcna.2005.06.002. Erratum in: Med Clin North Am. 2006 Jan;90(1):261-2. PMID: 16227063.
  27. Rosebush PI, Anglin RE, Richards C, Mazurek MF. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008 Aug;28(4):459-61. doi: 10.1097/JCP.0b013e31817ea9c1. PMID: 18626278.
  28. Zaretsky DV, Hunt JL, Zaretskaia MV, DiMicco JA. Microinjection of prostaglandin E2 and muscimol into the preoptic area in conscious rats: comparison of effects on plasma adrenocorticotrophic hormone (ACTH), body temperature, locomotor activity, and cardiovascular function. Neurosci Lett. 2006 Apr 24;397(3):291-6. doi: 10.1016/j.neulet.2005.12.032. Epub 2006 Jan 6. PMID: 16406311.
  29. Baltacıoğlu M, Hocaoğlu Ç. Nöroleptik malign sendromnedir? Tanıvetedaviyaklaşımları. Journal of contemporary medicine. 2019;9(4):424-431
  30. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717-25. doi: 10.1176/ajp.146.6.717. PMID: 2567121.
  31. Lu TC, Chu PL, Wu CS, Tsai KC, Chen WJ. Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder. J Formos Med Assoc. 2006 Jan;105(1):90-3. doi: 10.1016/S0929-6646(09)60115-7. PMID: 16440077.
  32. Kösem B. TekdozvenlafaksinkullanımınabağlıgelişenNöroleptik malign sendrom. Yeni Tıp Dergisi. 2014.
  33. Woods G, Taggart C, Boggs R, Cadden I. Neuroleptic malignant syndrome associated with quetiapine and venlafaxine use: a case report and discussion. Ther Adv Psychopharmacol. 2013 Feb;3(1):53-5. doi: 10.1177/2045125312464386. PMID: 23983992; PMCID: PMC3736958.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership